The Strategic Council is a team of executive leaders who will provide unparalleled access to high-calibre commercial, payer, and patient advocacy expertise. These team members are Dawn Lee, Eric Lowe (OBE), and Dr Susan Suponcic.
Industry and academic skills abound in the Strategic Council:
- Dawn Lee is a distinguished Associate Professor of Health Economics and Health Policy at the Peninsula Technology Assessment Group (PenTAG). A current lead for an Evidence Review Group and serving as a NICE committee member, Dawn is an exceptional health economist with a track record of over 50 UK Health Technology Assessment submissions and global expertise spanning more than 30 countries.
- Eric Low, OBE is a visionary key opinion leader with an unwavering commitment to patient outcomes and rare diseases' prevention and curability. He is a leading authority in orphan drugs and melanoma medical research, local market access, and patient organisations in the UK. Notably, he founded Myeloma UK and currently runs a consultancy specialising in strategic market access, healthcare policy, and patient engagement.
- Dr Susan Suponcic brings a wealth of US and Global pricing and market access commercialisation expertise. Her vast experience across US pharmaceutical companies and global consultancies will be leveraged to provide FIECON clients access to specific US launch and commercial expertise.
The introduction of the FIECON Strategic Council has redefined the standard of excellence for strategic advice and support for the life sciences industry. Clients can look forward to unprecedented access to commercial titans and an accelerated path to resolving their challenges in global markets, in particular, dynamic "must win" US, UK, and European markets.The formation of the council underscores FIECON’s continued commitment to delivering industry-best results, experiences, and partnerships to clients in the pharmaceutical and Med-tech industry.
